Cancer drug discovery through high-throughput screening at a major cancer center
Official title: Cancer Pharmacologist and HTS Scientist
Funded at Vanderbilt University · NIH-11446874 · Data updated 2026-11-12
Aims to accelerate identifying new cancer drugs using high-throughput screening and genome-wide approaches at Vanderbilt’s cancer center.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 19, 2016 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $155,075 |
| NIH project number | 2R50CA211206-11 |
| Project ID | NIH-11446874 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with cancer whose tumors could be studied for target validation or who may benefit from future targeted therapies identified by this research.
✕Less likely to help
Patients not eligible for or not impacted by the specific drug-target findings or later-stage trials may not receive direct benefit.
What this research studies
This project centers on a high-throughput screening core that partners cancer biology with chemical biology to find new drug targets and understand how cancer cells respond to therapies. It uses large-scale compound libraries, functional genomics (siRNA/CRISPR), and high-content imaging to reveal how drugs affect cancer cells. The work involves collaboration among researchers, gives training to students and postdocs, and builds on a track record of successful screens and publications. The goal is to translate basic discoveries into actionable targets for cancer treatment.
Why it matters
Potential benefit: Potentially faster discovery of new cancer therapies and deeper understanding of how drugs work in cancer cells.
How similar studies have gone: Previous high-throughput screening efforts have yielded numerous publications and enabled subsequent grant-funded studies and clinical trials in cancer.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Bauer, Joshua a. — Vanderbilt University
- Study coordinator: Bauer, Joshua a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.